Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2026 09:00 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high...